Drugs that are aromatase inhibitors and selective estrogen receptor modulators, such as tamoxifen and raloxifene, are actively studied for primary prevention of breast cancer in populations with higher incidence of breast cancer [6], but the risk of side effects could outweigh the benefits among Asian women with lower risk. The gene discussed is CYP19A1; the disease is breast cancer.